Balancing the risks and benefits of infliximab in the treatment of inflammatory bowel disease

Sandborn, W. J.; Loftus, E. V.
June 2004
Gut;Jun2004, Vol. 53 Issue 6, p780
Academic Journal
Infliximab, a monoclonal antibody to tumor necrosis factor α, is an important advance in the treatment of Crohn's disease. The efficacy of infliximab for the treatment of ulcerative colitis is still unclear. All patients in the study initially received at least one induction dose of infliximab. Thus safety data in patients with Crohn's disease treated only with placebo who were naive to infliximab was available in only 34 of 1081 patients enrolled in placebo controlled trials.


Related Articles

  • Lactobacillus GG in inducing and maintaining remission of Crohn's disease. Schultz, Michael; Timmer, Antje; Herfarth, Hans H.; Sartor, R. Balfour; Vanderhoof, Jon A.; Rath, Heiko C. // BMC Gastroenterology;2004, Vol. 4, p5 

    Background: Experimental studies have shown that luminal antigens are involved in chronic intestinal inflammatory disorders such as Crohn's disease and ulcerative colitis. Alteration of the intestinal microflora by antibiotic or probiotic therapy may induce and maintain remission. The aim of...

  • Use of the Crohn's disease activity index in clinical trials of biological agents. Freeman, Hugh James // World Journal of Gastroenterology;7/14/2008, Vol. 14 Issue 26, p4127 

    The Crohn's disease activity index (CDAI) has been commonly used to assess the effects of treatment with different agents in Crohn's disease (CD). However, these studies may be compromised, if the results compared to a placebo or standard therapy group (in the absence of a placebo) substantially...

  • Vedolizumab as induction and maintenance therapy for Crohn's disease/Vedolizumab as induction and maintenance therapy for ulcerative colitis.  // Inflammatory Bowel Disease Monitor;2014, Vol. 14 Issue 2, p55 

    Vedolizumab is a humanized immunoglobulin G mono-clonal antibody that targets the α4β7 integrin, thus inhibiting leukocyte adhesion and selectively reducing intestinal inflammation without enhancing opportunistic brain infections. These two articles report the results of the GEMINI 1...

  • A Pooled Analysis of Infections, Malignancy, and Mortality in Infliximab- and Immunomodulator-Treated Adult Patients With Inflammatory Bowel Disease. Lichtenstein, Gary R; Rutgeerts, Paul; Sandborn, William J; Sands, Bruce E; Diamond, Robert H; Blank, Marion; Montello, Jennifer; Tang, Linda; Cornillie, Freddy; Colombel, Jean-Frédéric // American Journal of Gastroenterology;Jul2012, Vol. 107 Issue 7, p1051 

    OBJECTIVES:The objective of this study was to analyze the safety of long-term infliximab treatment, with/without concomitant immunomodulators, across Crohn's disease (CD) and ulcerative colitis (UC) clinical trials.METHODS:To maximize sample size, we pooled primary safety data across 10 CD or UC...

  • GASTRO-HEP News. Alleman, Samantha // Gastroenterology & Hepatology;Sep2015, Vol. 11 Issue 9, p581 

    This section offers news briefs in gastroenterology. A study done at the University of Amsterdam hospital in Amsterdam, the Netherlands revealed that high amounts of infliximab can result to decline in response to ulcerative colitis therapy among patients. The HEAT study of 701 patients...

  • Infliximab.  // Reactions Weekly;12/1/2007, Issue 1180, p22 

    The article describes the case of three patients who developed new-onset psoriasis while receiving IV infliximab. The first patient, a 40-year-old woman, had been receiving infliximab for 10 months for ulcerative colitis. She developed a scaly rash on her elbows, hands, feet, knees and trunk....

  • Adalimumab Induction Therapy for Crohn Disease Previously Treated with Infliximab. Sandborn, William J.; Rutgeerts, Paul; Enns, Robert; Hanauer, Stephen B.; Colombel, Jean-Frédéric; Panaccione, Remo; D'Haens, Geert; Li, Ju; Rosenfeld, Marie R.; Kent, Jeffrey D.; Pollack, Paul F. // Annals of Internal Medicine;6/19/2007, Vol. 146 Issue 12, p829 

    Background: Adalimumab, a fully human tumor necrosis factor (TNF) antagonist, is an effective treatment for patients with Crohn disease who are naive to the chimeric TNF antagonist, infliximab. No anti-TNF agent has been evaluated prospectively in patients with Crohn disease who had responded to...

  • Relationship of C-Reactive Protein With Clinical Response After Therapy With Ustekinumab in Crohn's Disease. Toedter, Gary P.; Blank, Marion; Yinghua Lang; Dion Chen; Sandborn, William J.; de Villiers, Willem J. S. // American Journal of Gastroenterology;Nov2009, Vol. 104 Issue 11, p2768 

    OBJECTIVES:Ustekinumab induction therapy was studied in a placebo-controlled trial of patients with Crohn's disease (CD; n=104). In patients receiving ustekinumab, 49% achieved clinical response at week 8 vs. 40% for placebo (P=0.34). In a subgroup of patients previously treated with infliximab...

  • Systemic antibodies towards mucosal bacteria in ulcerative colitis and Crohn's disease differentially activate the innate immune response. Furrie E; Macfarlane S; Cummings J H; Macfarlane G T // Gut;Jan2004, Vol. 53 Issue 1, p91 

    BACKGROUND AND AIMS: The mucosa in ulcerative colitis (UC) is replete with antibody producing plasma B cells and polymorphonuclear leucocytes (PMN). This combination of effector cells requires a crosslinking antigen to evoke an antibody driven PMN inflammatory response via their Fc receptors....


Read the Article


Sign out of this library

Other Topics